nuclear-news

“Medical isotopes help so many people every day. It’s critical to have a stable, multi-faceted supply chain to avoid unexpected disruptions to their availability,” said Paul Schaffer, Associate Laboratory Director, Life Sciences at TRIUMF and Associate Professor at UBC’s Faculty of Medicine. “The approval of cyclotron-produced technetium-99m by Health Canada is an important milestone for this Canadian innovation that will ultimately deliver direct benefit for Canadian patients.”

While the Health Canada approval brings new promise for patients and researchers, it also highlights an important chapter in Canadian innovation, one which saw a focused national research effort produce an effective solution to a global problem.

In 2009, following unplanned disruptions at NRU (which historically provided up to half of the world’s technetium-99m via molybdenum-99 generators), the Government of Canada initiated the Non-reactor-based Isotope Supply Contribution Program (NISP) which challenged researchers to find a new way to produce critical medical isotopes—in particular, technetium-99m.

The consortium’s proposal detailed a new and innovative technology to enable the production of technetium-99m using medical cyclotrons. These compact particle accelerators already operate in regional healthcare centres worldwide, producing isotopes by bombarding a target material with a proton beam and extracting the desired species. The process is safe and precise, employing stable targets and producing little to no long-lived radioactive waste. And, with the right target and extraction systems, these cyclotrons can be used to reliably create technetium-99m regionally and without the need for reactor-based materials.

“Cyclotron centres across Canada can produce these isotopes locally and on-demand, and we have shown the path that can be used to achieve regulatory approval,” said Francois Bénard, senior executive director of research at BC Cancer, professor of radiology and associate dean of research at UBC’s faculty of medicine. “The same approach can be followed at other sites in Canada and internationally. This has been a shared vision of many researchers across the country, and we have to recognize the many collaborators who worked for years to make this announcement possible.”